174 related articles for article (PubMed ID: 35867199)
21. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
Nirogi R; Benade V; Goyal VK; Pandey SK; Mohammed AR; Shinde A; Dogiparti D; Ravula J; Jetta S; Palacharla VRC
Clin Drug Investig; 2022 Sep; 42(9):747-762. PubMed ID: 35963959
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
23. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study.
Manitpisitkul P; Shalayda K; Russell L; Sanga P; Solanki B; Caruso J; Iwaki Y; Moyer JA
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):712-726. PubMed ID: 29125703
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Knöchel J; Nelander K; Heijer M; Lindstedt EL; Forsberg GB; Whatling C; Shimada H; Han DS; Gabrielsen A; Garkaviy P; Ericsson H
Clin Drug Investig; 2021 Oct; 41(10):895-905. PubMed ID: 34546534
[TBL] [Abstract][Full Text] [Related]
26. A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects.
Jeon Y; Lee N; Baek S; Choi J; Jhee S; Lee H
Drugs R D; 2022 Mar; 22(1):71-87. PubMed ID: 34993933
[TBL] [Abstract][Full Text] [Related]
27. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Guanfacine Extended-Release Formulation in Healthy Japanese and Caucasian Male Adults.
Matsuo Y; Okita M; Ermer J; Wajima T
Clin Drug Investig; 2017 Aug; 37(8):745-753. PubMed ID: 28421383
[TBL] [Abstract][Full Text] [Related]
29. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
[TBL] [Abstract][Full Text] [Related]
30. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects.
Zhao Q; Brett M; Van Osselaer N; Huang F; Raoult A; Van Peer A; Verhaeghe T; Hust R
J Clin Pharmacol; 2002 Sep; 42(9):1002-10. PubMed ID: 12211216
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
Yamahira N; Frost C; Fukase H; Yu Z; Wang J; Pursley J; LaCreta F; Hiraoka M
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
[TBL] [Abstract][Full Text] [Related]
32. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
[TBL] [Abstract][Full Text] [Related]
33. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
[TBL] [Abstract][Full Text] [Related]
34. Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
Fouqueray P; Perrimond-Dauchy S; Bolze S
Clin Pharmacokinet; 2020 Oct; 59(10):1261-1271. PubMed ID: 32270440
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects.
Trivedi A; Malik FI; Mackowski M; Hutton S; Aoki M; Abbasi S; Dutta S; Lee E
Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):759-770. PubMed ID: 34415561
[TBL] [Abstract][Full Text] [Related]
36. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function.
Kitamura A; Yumizaki T; Kondo T; Sekino H; Kakuyama H
J Clin Pharmacol; 2023 Jul; 63(7):807-816. PubMed ID: 36847203
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T
Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536
[TBL] [Abstract][Full Text] [Related]
39. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
[TBL] [Abstract][Full Text] [Related]
40. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.
Watabe M; Cheng YF; Nilsson D; Itoh Y; Kumagai Y
Curr Med Res Opin; 2007 Aug; 23(8):1849-57. PubMed ID: 17605894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
